SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Merrimack Pharmaceuticals, Inc. (MACK)

Add MACK Price Alert      Hide Sticky   Hide Intro
Moderator: $Pistol Pete$
Search This Board: 
Last Post: 5/19/2017 6:11:13 PM - Followers: 70 - Board type: Free - Posts Today: 0

Welcome to Merrimack Pharmaceuticals, Inc. (MACK) Board!!!

At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.


       Our Leadership

           Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare                  industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and                    private  management from Yale University and a BA from Stanford University.

           Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008            to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and                        specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA            in theology from Cambridge University and a BA from Cambridge University.

           Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice                  specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010.                Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins            holds an  MBA and a BS from McGill University.

           Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at                the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after                    serving on the  faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems            biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.

           William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business            services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From                        September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and              a BA from Williams College.

           Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009            to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational                models of  signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in                  Germany.

           Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development                roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University                and a BS from  Bates College.

          William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of               Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007.             Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional                             Accounting and a BA from Williams College.

     Contact Us

        One Kendall Square
        Building 700, Suite B7201
        Cambridge, MA 02139
        Phone: 617-441-1000



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MACK News: Statement of Changes in Beneficial Ownership (4) 05/12/2017 05:01:35 PM
MACK News: Quarterly Report (10-q) 05/10/2017 04:56:51 PM
MACK News: Merrimack Reports First Quarter 2017 Financial Results 05/10/2017 06:45:00 AM
MACK News: Merrimack Announces Timing of First Quarter 2017 Investor Conference Call 05/02/2017 04:30:00 PM
MACK News: Amended Annual Report (10-k/a) 05/01/2017 02:57:13 PM
#601  Sticky Note $MACK Merrimack Declares $140M Special Dividend in Connection $Pistol Pete$ 04/13/17 10:54:58 AM
#708   Thanks - you too $Pete love your neighbor 05/19/17 06:11:13 PM
#707   $MACK after market hour so far at $3.62. $Pistol Pete$ 05/19/17 06:10:25 PM
#706   Would need a genie for that huh?? PigeonToad 05/19/17 06:08:30 PM
#705   Count me in. I am holding 70,000 shares here $Pistol Pete$ 05/19/17 03:00:28 PM
#704   We are all members of the $MACK big roger wilco 05/19/17 01:44:18 PM
#703   $MACK Thank you my Friend and I think $Pistol Pete$ 05/19/17 01:38:59 PM
#702   Another good call on the move higher today. Rock_nj 05/19/17 12:58:14 PM
#701   nice $$$ love your neighbor 05/18/17 04:39:42 PM
#700   $MACK 72,394 shares bought at $3.575 after market. $Pistol Pete$ 05/18/17 04:38:06 PM
#699   $MACK Merrimack Pharmaceuticals Inc (MACK) Upgraded to H $Pistol Pete$ 05/18/17 01:02:54 AM
#698   sweet love your neighbor 05/17/17 01:49:56 PM
#697   Awesome....remember you will get your dividend on May $Pistol Pete$ 05/17/17 01:49:04 PM
#696   got some today. looking forward to the 26th. love your neighbor 05/17/17 01:48:12 PM
#695   No problem at all. Glad to be able $Pistol Pete$ 05/17/17 01:44:19 PM
#694   Makes sense. Thanks Pete. Rock_nj 05/17/17 01:39:08 PM
#693   $MACK here is the breakdown to get dividend 1. $Pistol Pete$ 05/17/17 11:27:08 AM
#692   I got it now. I will explain later $Pistol Pete$ 05/17/17 11:06:51 AM
#691   Ex dividend date is May 30th. Pay Rock_nj 05/17/17 11:06:28 AM
#690   Let me call my broker $Pistol Pete$ 05/17/17 10:50:45 AM
#689   Ex dividend actually comes after the dividend pay Rock_nj 05/17/17 10:50:09 AM
#688   I am little confuse though. Is May 26 $Pistol Pete$ 05/17/17 10:38:12 AM
#687   From what I've read, the record Day is Rock_nj 05/17/17 10:34:14 AM
#686   I believe today is the last day to $Pistol Pete$ 05/17/17 10:29:41 AM
#685   I hear you well Go $MACK $Pistol Pete$ 05/17/17 09:32:28 AM
#684   I think you've had a massive buy in, FreezeThese 05/17/17 07:58:41 AM
#683   What do we expecting here? Do you think $Pistol Pete$ 05/16/17 04:53:17 PM
#682   A special div, on a $3 stock ... FreezeThese 05/16/17 03:44:04 PM
#681   Yep $Pistol Pete$ 05/16/17 03:29:29 PM
#680   Bad idea to sell. Stocks usually rally Rock_nj 05/16/17 03:26:08 PM
#679   First one to sell May 30th wins ... FreezeThese 05/16/17 11:05:01 AM
#678   $MACK can't wait to see it hit $.4.5 $Pistol Pete$ 05/15/17 10:41:09 PM
#677   next 2 days going to be fun in novicetrader 05/15/17 10:36:38 PM
#676   No problem at all and good luck to $Pistol Pete$ 05/15/17 07:06:11 PM
#675   Just dropped by to give you a personal ReadyToRumble 05/15/17 06:15:13 PM
#674   I'm good with $5 roger wilco 05/15/17 02:12:08 PM
#673   That's awesome $Pistol Pete$ 05/15/17 02:08:04 PM
#672   Yep I see $5 by Wed Wreckingballer 05/15/17 11:22:45 AM
#671   $MACK $4 is on the deck $Pistol Pete$ 05/15/17 11:14:59 AM
#670   All shares are locked so I think they $Pistol Pete$ 05/13/17 03:21:33 PM
#669   Was it a no brainer? Shorts had to EM 05/13/17 02:55:03 PM
#668   oh,so then shorts also have lost their window novicetrader 05/13/17 12:57:12 PM
#667   $MACK Agreed and I am thinking at least $Pistol Pete$ 05/13/17 12:56:54 AM
#666   That's incorrect as all trades whether buy, sell, Wreckingballer 05/13/17 12:32:31 AM
#665   No problem my Friend. Bottom line is short $Pistol Pete$ 05/12/17 11:12:22 PM
#664   That's probably logical(Wednesday being the Record date).A BUY novicetrader 05/12/17 11:04:05 PM
#663   I think they has until Tues to cover $Pistol Pete$ 05/12/17 10:46:29 PM
#662 PLUTUS 05/12/17 10:32:04 PM
#661   have heard today was last day to BUY novicetrader 05/12/17 10:16:33 PM
#660   Keep me posted $Pistol Pete$ 05/12/17 08:36:40 PM
#659   I heard black rock bought a big chunk. Rock_nj 05/12/17 08:29:48 PM